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Cell transplantation is a strategy with great potential for the treatment of Parkinson’s disease, and many types of stem cells,
including neural stem cells and embryonic stem cells, are considered candidates for transplantation therapy. Mesenchymal stem
cells are a great therapeutic cell source because they are easy accessible and can be expanded from patients or donor mesenchymal
tissues without posing serious ethical and technical problems. They have trophic eﬀects for protecting damaged tissues as well as
diﬀerentiation ability to generate a broad spectrum of cells, including dopamine neurons, which contribute to the replenishment
oflostcellsinParkinson’sdisease.Thispaperfocusesmainlyonthepotentialofmesenchymalstemcellsasatherapeuticcellsource
and discusses their potential clinical application in Parkinson’s disease.
1.Introduction
In the central nervous system, where neurons become
postmitotic after birth, little structural and functional regen-
eration occurs. Although intrinsic neural stem cells and
progenitor cells proliferate and diﬀerentiate after damage,
their contribution is insuﬃcient for functional recovery
[1]. Protective treatment eﬀectively prevents the progressive
loss of dying neuronal cells in the earlier stages of neural
degeneration, but in advanced stages, transplantation of
cells with neuronal properties is considered the ultimate
solution for degenerative diseases. Parkinson’s disease (PD)
is a neurodegenerative disease caused by the loss of midbrain
dopamine neurons with a subsequent decrease in striatal
dopamine [2]. Pharmacologic treatment with the dopamine
precursor L-DOPA is eﬀective in the earlier stages, but
reduced eﬃcacy and the development of motor complica-
tions in the later stages require treatment alternatives such
as dopamine neuron transplantation [3].
Transplantation of embryonic mesencephalic cells or
fetal dopamine cells into the striatum of PD patients was
initiated in the 1980s [2]. Some studies have reported neg-
ative eﬀects of human embryonic or fetal dopamine neuron
transplantation, that is, clinical beneﬁts were recognized
in younger patients but not in older patients, and more
than half of the transplanted patients developed dyskinesia
that persisted after overnight withdrawal of dopaminergic
medication [4, 5]. On the other hand, other groups have
reported positive results of the transplantation of embryonic
or fetal dopamine neurons. Grafts of embryonic dopaminer-
gic neurons can survive and exert functional eﬀects for up to
several years after surgery in the brain of patients with PD
[6, 7]. In addition, suﬃcient recovery with the integration
and reinnervation of grafts is observed in positron emission
tomography [8]. While these transplantation strategies raise
hopes for reverting PD, there are limiting factors that
preclude the therapeutic use of embryonic and fetal cells,
such as ethical issues and obtainable cell numbers. Only
smallnumbersofdopamineprecursorscanbecollectedfrom
donor embryonic or fetal tissues. Therefore, there is a great
need for generating large pools of dopamine neurons or
precursors for transplantation.
Stem cells have recently aroused a great deal of interest
because of their potential to diﬀerentiate into dopamine
neurons either by spontaneous diﬀerentiation or through
certaininductionprotocols[3].Neuralstemcells(NSCs)and
embryonic stem (ES) cells have been studied for more than
decade. More recently, several intensive studies have focused2 Parkinson’s Disease
on the use of mesenchymal stem cells (MSCs). In this paper,
we describe the advantages and disadvantages of each stem
cell type with regard to its potential use for PD treatment,
focusing mainly on MSCs.
2. MSCs andTheir Properties
MSCs are adult stem cells that belong to the mesodermal
lineage and are traditionally found in the bone marrow as
bone marrow mesenchymal stem cells (BMSCs) [9]. MSCs
can also be isolated from other mesenchymal tissues, such as
umbilical cord, dermis, adipose tissue, and peripheral blood
[10]. Morphologically, MSCs have long thin cell bodies with
a large nucleus similar to ﬁbroblasts. As with some other
tissue stem cells, MSCs have a high capacity for self-renewal
while maintaining multipotency [11]. Diﬀerent from other
stem cells such as ES cells and NSCs; however, MSCs can be
obtained from patients (for autocell transplantation) as well
as from healthy donors (for allo-transplantation) by using
mesenchymaltissuessuchasfat,bonemarrow,andumbilical
cord (Figure 1).Therefore,MSCsarearealisticcellsourcefor
regenerative medicine.
Among the many kinds of MSCs, BMSCs are the most
well studied. BMSCs can be cultivated from bone marrow
aspirates as plastic adherent cells in vitro [11]. The great
beneﬁt of BMSCs is that they are easily accessible through
aspiration of the patient’s bone marrow, so that the use of
BMSCs avoids ethical issues, facilitating their application
both for auto- and allo-transplantation. BMSCs are also
easily expanded on a large scale, which is very convenient
for clinical use (e.g., 20 to 100mL of bone marrow aspirate
provides 107 BMSCs within several weeks) [12].
For cell-based therapy, MSCs have two major eﬀects:
at r o p h i ce ﬀect that is mediated by the various types of
trophic factors and cytokines produced by MSCs [13]a n d
diﬀerentiation to generate a broad spectrum of cells for the
replenishment of lost cells [14]. MSCs normally provide
trophic factors to support hematopoietic stem cells in the
bone marrow, thus their trophic eﬀe c ti sp a rto ft h e i rn o r m a l
function. MSCs are multipotent stem cells that are known
to diﬀerentiateintoosteocytes,chondrocytes,andadipocytes
[11]. These diﬀerentiations are within the same mesodermal
lineage, but recent reports demonstrated that MSCs show
unorthodox diﬀerentiation into ectodermal and endodermal
cells [15–19]. These ﬁndings stimulated the advancement
of regenerative medicine aimed at the generation of desired
cells from MSCs. To date, various cell types, such as
mesodermal lineage cells (e.g., bone, cartilage, adipocytes,
skeletal muscles, and cardiomyocytes), as well as endodermal
lineage cells (e.g., airway epithelial cells, hepatocytes, and
insulin-producing cells) and ectodermal lineage cells (e.g.,
neuronal cells and epidermal cells) have been induced from
MSCs in vitro by the use of cytokines, trophic factors or gene
introduction [15–22].
Adult stem cells typically generate the cell types of the
tissue in which they reside, and thus the range of their dif-
ferentiation capabilities is considered limited. For example,
hematopoietic stem cells generate blood cells, and NSCs
generate neurons and glial cells [23, 24]. MSCs diﬀer from
these typical somatic stem cells because, as stated previously,
theydiﬀerentiate not only into the same mesodermal-lineage
cells of bone, cartilage, and adipocytes, but also into other
lineages of ectodermal and endodermal cells. As MSCs can
generate cells representative of all three germ layers, it has
been debated whether MSCs are pluripotent cells. Recently,
pluripotent stem cells named multilineage-diﬀerentiating
stress enduring (Muse) cells were found among adult human
mesenchymal stem cells (BMSCs and skin ﬁbroblasts) as well
as in mesenchymal tissues (bone marrow and dermis) [25].
Muse cells are capable of self-renewal and of diﬀerentiating
into cells representative of all three germ layers from a
single cell, which may partly explain the broad spectrum of
diﬀerentiation observed in MSCs [25].
3. MSCs andTheir Differentiation Ability
The possibility of MSC plasticity and “transdiﬀerentiation”
wasinitiallydescribedfollowinginvivoexperimentsinwhich
transplanted donor bone marrow-derived cells diﬀerentiated
into glial cells in the recipient brain [26]. While some studies
suggested that MSCs are plastic based on their expression of
cell-speciﬁc markers, the functions of the transdiﬀerentiated
cells were not clearly demonstrated in other cases. Moreover,
questions have been raised regarding the interpretation of
“transdiﬀerentiation” of infused cells into neuronal lineage
cells because some investigators have suggested that the
transdiﬀerentiation observed was rather a result of fusion
between infused bone marrow cells and the host brain cells
[27, 28]. Despite this uncertainty, accumulating evidence
supports the broad diﬀerentiation of MSCs both in vivo
and in vitro. Based on the frequency and ratio of MSCs
integrated and diﬀerentiated into the host tissue, fusion
alone cannot explain all of the phenomena observed after
MSC infusion. Furthermore, experiments using a Cre-lox
system clearly demonstrated that MSCs can transdiﬀeren-
tiate into epithelial cells in vivo without fusion [29]. In
vitro diﬀerentiation of MSCs provides further evidence for
MSC transdiﬀerentiation because there are no preexisting
diﬀerentiated cells to be fused at the beginning of induction
under culture conditions.
4. BMSCs
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model aimed at ameliorating PD symptoms. As mentioned
previously, BMSCs have trophic eﬀects that are mediated
by the various types of trophic factors and cytokines they
produce. Therefore, naive adult BMSCs engrafted to the
striatum induce partial but not drastic recovery of the
dopamine pathway in a rat model of PD (Figure 1)[ 30–
34]. Findings from a human pilot study of autologous
naive BMSC transplantation performed in PD patients and
followed for up to 36 months indicated a certain degree of
amelioration of symptoms with no tumor formation [35].
While BMSCs have advantages over some other stem cells
regarding their safety, easy accessibility, and trophic eﬀects,Parkinson’s Disease 3
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Figure 1: Strategy for MSC transplantation in PD patients. MSCs can be obtained from fat tissue or bone marrow aspirates of Parkinson’s
disease (PD) patients and are applicable for autocell transplantation. They can also be obtained from fat tissue, bone marrow aspirates, and
umbilical cord of healthy donors for allocell transplantation. Naive MSCs can be directly transplanted into the striatum of PD patients, but
this treatment exerts temporary trophic eﬀects. Gene-introduced MSCs also have trophic eﬀects for the replenishment of lost cells. MSCs
are able to be induced into dopamine neurons that will contribute to the functional recovery of PD>.
naive BMSC transplantation has limitations for deﬁnitive
care because most of the transplanted cells do not survive
in vivo for a long time, and thus the trophic eﬀects gradually
decrease.
In addition to naive BMSC transplantation, genetically
modiﬁed BMSCs have been applied to the PD model
(Figure 1). Cells genetically modiﬁed to produce L-DOPA
or neurotrophic factors such as neurotrophins and glial cell
line-derived neurotrophic factor (GDNF) are reported to be
somewhat eﬀective for the amelioration of PD symptoms
[36–39].
WhilenaiveBMSCtransplantationisindeedasimpleand
accessible method for providing trophic eﬀects, dopamine
neurons would be a rational ultimate solution to PD
(Figure 1). Naive BMSCs, in general, do not diﬀerentiate
spontaneously in vivo after transplantation. Even if they
did diﬀerentiate, the ratio of diﬀerentiated cells would be
extremely low [26]. For practical use, it would be more
desirable to establish a speciﬁc system for inducing BMSCs
to produce dopamine neurons prior to transplantation.
There are several reports of the induction of dopamine
neurons from BMSCs [40–42], but in these reports the
eﬀectiveness of the induced cells in vivo was not evaluated
by transplanting them into a PD model. Another study
reported that MSCs induced into immature neurons using
basic ﬁbroblast growth factor (bFGF), epidermal growth
factor, platelet-derived growth factor, sonic hedgehog, FGF-
8, GDNF, or the reagents butylated hydroxyanisole and
dibutyryl cAMP were transplanted into a PD model, but
these immature neurons did not eﬀectively ameliorate the
PD symptoms [43, 44]. In this manner, growth factor-
based methods allow MSC diﬀerentiation toward immature
neuronal-likecells,butarenoteﬃcientinPDmodels.Onthe
other hand, when MSCs were induced into fully functional
dopamine neurons and then transplanted into a PD model,
they were clearly eﬀective, as described in the next section
[17].
5. Induction of FunctionalDopamine
Neurons from BMSCs
A system to speciﬁcally induce dopamine neurons from
BMSCs was reported (Figure 2)[ 17]. This system ﬁrst gen-
erates postmitotic functional neuronal cells with a very high
eﬃciency without contamination by glial cells. The resulting
neuronal cells are then further induced into dopamine
neurons. The induction is achieved by lipofection of a
plasmid containing a Notch1 intracellular domain (NICD)
and G418 selection, followed by the administration of a
speciﬁc combination of trophic factors and cytokines [17,
45].
Naive BMSCs initially show little expression of the glu-
tamate transporter GLAST, 3-PDGH, and nestin, which are
markers for neuronal progenitor cells (NPCs), but BMSCs
express these markers substantially after introduction of
NICD (Figure 2). Based on a luciferase promoter assay,
promoter activities of 3-PDGH, which are reported to be
high in radial glia and neuroepithelial cells, as well as those
of the neuronal marker NeuroD, are signiﬁcantly increased
(up to 10 times) in BMSCs after NICD introduction. These
ﬁndings suggest that the introduction of NICD into the
cells induces BMSCs to acquire the characteristics of NPCs
(Figure 2)[ 17, 46].4 Parkinson’s Disease
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Figure 2: Induction of dopamine neurons from MSCs. After NICD introduction, MSCs become similar to NPCs, expressing the NPC
markers nestin, GLAST, 3-PDGH, and neuroD. After cytokine stimulation (bFGF, CNTF and forskolin (FSK)), cells become postmitotic
neurons expressing neuronal markers such as neuroﬁlament, Tuj-1, and MAP-2. The administration of GDNF induces neurons to become
dopamine neurons (TH), which are useful in the Parkinson’s disease model. Pictures from J Clin Invest 113 (2004) 1701–1710 and J Cereb
Blood Flow Metab 29 (2009) 1409–1420 [17, 46].
When NICD-introduced BMSCs are expanded and then
stimulated with trophic factors (bFGF, forskolin, and ciliary
neurotrophic factor (CNTF)) for several days, approximately
96% of the cells extend neurites and diﬀerentiate into
postmitotic neuronal cells. These cells are positive for the
neuronal markers MAP-2ab, neuroﬁlament, and Tuj1, and
mostimportantly,actionpotentialswererecordedinthecells
in a patch clamp experiment, suggesting that these induced
cells are functional neuronal cells (Figure 2)[ 17, 47].
At this stage, cells positive for tyrosine hydroxylase
(TH), a marker for dopamine neurons, accounted for ratios
of only approximately 4%. After GDNF stimulation, the
cells positive for TH substantially increased up to ∼60%
(Figure 2). Furthermore, other dopamine markers, Nurr-1,
Lmx1b, En1, and Ptx3, were elevated in these TH-positive
cells [17]. The dopamine release upon depolarization in
vitro measured by high-performance liquid chromatography
indicated that the induced cells released dopamine into the
culture media in response to high K+-depolarizing stimuli.
These ﬁndings indicate that functional dopamine neurons
can be eﬃciently induced from BMSCs (Figure 2)[ 17].
The adaptability of BMSCs to an in vitro environment
and their proliferative activity diﬀer among species. In
general, human and rat BMSCs can stably proliferate in vitro
while those of monkeys and mice are vulnerable to manip-
ulation, often resulting in unsuccessful NICD gene intro-
duction by lipofection due to the cytotoxicity of lipofection.
Cell damage during the induction procedure is a barrier to
realizingcell-basedtherapy,andthus,geneintroductionwith
higher eﬃciency and safety is strongly needed for practical
use. Spermine/pullulan-mediated reverse transfection is an
eﬀective method for introducing plasmid genes, even into
vulnerable cells, with high eﬃciency and low cytotoxicity. In
fact, introduced NICD genes are successfully transcribed and
expressed as protein in the cytoplasm of monkey and mice,
as well as in human BMSCs, with extremely low levels of
cytotoxicity [48]. This system is also eﬀective for inducing
dopamine neurons from monkey and mice BMSCs. NICD
introductionintoBMSCsusingspermine/pullulan-mediated
reverse transfection followed by cytokine administration
successfully induces neuronal cells that show dopamine
release in high-performance liquid chromatography [48].
Thus, the spermine/pullulan-mediated reverse transfection
is an ideal alternative method to induce dopamine neurons
f r o mB M S C so faw i d er a n g eo fs p e c i e s .
6. TransplantationofBMSC-DerivedDopamine
N e ur o nsint oPDM od el s
Induced dopamine neurons (1 × 105 cells) from either
rodent or human (under the control of immunosuppres-
sant) BMSCs were transplanted into the striatum of a
PD model rat induced by 6-hydroxydopamine (6-OHDA)
[17]. Unilateral administration of 6-OHDA into the medial
forebrain bundle selectively destroys dopamine neurons in
the substantia nigra, leading to quantiﬁable changes in
rotational behavior and providing a useful and commonly
used model of PD. Model rats receiving a transplanta-
tion demonstrated a substantial decrease in apomorphine-
induced rotation behavior, and nonpharmacologic behavior
tests, such as adjusting step and paw-reaching tests, also
demonstrated signiﬁcant improvements in both rodent and
human induced cell transplantation. Grafted dopamine
neurons migrated and extended beyond the injected site,Parkinson’s Disease 5
and approximately 30% of the cells remained in the stria-
tum 10 weeks after transplantation. The grafted striatum
showed the migration of GFP-positive transplanted cells that
expressed neuroﬁlament, TH, and DAT. Brain slice culture
experiments demonstrated the production of dopamine in
the transplanted brains. No tumor formation was observed
in the brain, demonstrating that dopamine neurons induced
from BMSCs do not have the ability to form tumors [17].
In summary, introduction of NICD followed by bFGF,
CNTF, forskolin, and GDNF administration can eﬃciently
induce functional dopamine neurons that lead to functional
recovery after transplantation in a rodent model of PD.
Notch signaling inhibits neuronal diﬀerentiation and
promotes glial diﬀerentiation during development [49].
Although the above discussed induction system seems
inconsistent with the well-known actions of Notch signaling,
it is presumed that cell susceptibility to Notch signaling
in MSCs is diﬀerent from that of cells in the process of
normal neuronal development. Distinct cellular responses
to Notch signals; for example, the protein repertoire and
active factors, might be quite diﬀerent between conventional
NPCs and BMSCs. In fact, neuronal basic helix-loop-helix
factors (Mash1, Math1, and neurogenin1), together with the
glial factors Hes1, Hes5, STAT1, and STAT3, are detected
in naive BMSCs in reverse transcription-polymerase chain
reaction analyses, while after NICD transfection, expression
of STAT1 and STAT3 is downregulated and expression of
Mash1, Math1, and neurogenin1, as well as Hes1 and Hes5,
is retained in the BMSCs [17]. Although it is believed that
the major intracellular eﬀect of NICD introduction is the
activation of Hes1 and Hes5, the introduction of either Hes1
or Hes5 to BMSCs, instead of NICD, does not induce NPC
marker-positivecells.Incontrast,administrationoftheJanus
kinase (JAK)/STAT inhibitor WHI-P131, instead of NICD
transfection, successfully produces NPC-like cells, which
are partially induced to be MAP2-antibody-positive cells
with neurite-like processes after additional trophic factor
induction [17]. These facts suggest that the downregulation
ofSTATexpressionbyNICD-transfectioniscloselyrelatedto
the transformation of MSCs to NPC-like cells and that Hes
activity is not involved in this process.
7. Other Kinds of MSCs andPD
The umbilical cord and adipose tissues are other realistic
sources of MSCs. Mesenchymal tissues of the umbilical cord,
so-called Wharton’s jelly, as well as fat tissues, contain an
abundance of MSCs. These cells have an advantage over
BMSCs in that the umbilical cord derives from postnatal
tissue that is discarded after birth, and thus cell collection
is not an invasive procedure for donors. Adipose tissue,
which is easily obtained from liposuction, also contains large
amountsofMSCscalledadipose-derivedstemcells(ADSCs).
Because of the ability of umbilical cord mesenchymal stem
cells (UC-MSCs) and ADSCs to diﬀerentiate into other cell
types and to proliferate, these cells are considered to be a
practical source for cell-based therapies.
In ADSCs, Tuj-1-positive cells, but not fully diﬀerenti-
ateddopamineneurons,induced,andtransplantedintoaPD
model,demonstratedthattheseneuron-likecellsareeﬀective
for treating PD to a certain degree after transplantation [50].
As for UC-MSCs, transplantation of naive cells and cells
genetically modiﬁed to produce VEGF were partly eﬀective
[51–53]. The potential of UC-MSCs to diﬀerentiate into
neuronal cells does not diﬀer from that of BMSCs, and
dopamine neurons can be induced from UC-MSCs using
neuron-conditioned medium, sonic hedgehog, and FGF-8.
Those cells are also eﬀective in PD models [54–56].
8.MSCs andClinicalStudies
A human pilot study was performed using BMSCs. Autolo-
gous naive BMSCs were transplanted into PD patients and
the patients were followed for up to 36 months. This clinical
trial resulted in partial symptom amelioration without evi-
dence of tumor formation or other side eﬀects [35]. Clinical
studies of MSCs have just begun, and there is a strong need
to accumulate results regarding MSC transplantation and its
eﬃcacy.
9.NSCs
NSCsar eanattracti v esour c eforc ellr eplac ementtherap yfor
PDbecausetheyhavetheabilitytodiﬀerentiateintoneurons,
astrocytes, and oligodendrocytes as well as into dopamine
neurons[23,57].NSCscanbeisolatedfromdiﬀerentregions
of the fetal brain as well as from the ventricular wall and the
hippocampal dentate gyrus in the adult brain so that they
can be harvested both from fetal and adult central nervous
systemtissues[3].A sNSCsar eablet oself-r enew ,theycanbe
maintained and expanded either as monolayers or as ﬂoating
aggregates called neurospheres [3]. Repeated expansion of
NSCs is, however, reported to decrease their potential to
diﬀerentiate into a variety of neuron subtypes, including
dopamine neurons. In particular, adult NSCs have lower
ability for diﬀerentiation than fetal NSCs [3]. Limitations
in the use of NSCs include ethical and histocompatibility
concerns for fetal NSCs and a limited supply of adult NSCs.
The ﬁrst results of genetic manipulation of NSCs
to generate dopamine neurons by overexpression of the
transcription factor Nurr 1 were reported in 1999 [57].
Gene introduction of the combination of Nurr1/Ngn2 or
Nurr1/Mash1 eﬀectively induced dopamine neurons, but the
induction eﬃciency was at most 1% so that these systems
seem not to be directly clinically applicable for PD [58, 59].
10.ESCells
ES cells have attracted great attention as an alternative
source for the generation of dopamine neurons because
they can be continually expanded with high potential for
diﬀerentiation. As they are pluripotent stem cells, they
are able to form all three embryonic germ layer lineages
following induced diﬀerentiation. Human ES cells were ﬁrst
derived in 1998 by Thomson [60] ,a n ds i n c et h e nm a n y
studies have focused on optimizing the diﬀerentiation of
ES cells into dopamine neurons. Among them, systematic6 Parkinson’s Disease
and eﬃcient induction systems for dopamine neurons have
been reported by several groups [61–64], and mouse ES cell-
derived dopamine neurons have been shown to survive and
function in a rat model of PD [65].
The prospect that ES cells can produce a suﬃcient
number of dopamine neurons for transplantation therapy
is particularly appealing, both for clinical and industrial
use. At the same time; however, their clinical application
is limited because of their ability to form tumors and the
ethical problems surrounding the use of using fertilized
human eggs to establish the ES cell lines. In addition,
autocell transplantation is unrealistic in the case of ES
cells.
In particular, several reports have raised an alert regard-
ing the tumor-forming ability of ES cells. For example,
engraftment of neurally selected ES cells to eyes exhibited
no morphologic alterations by 2 and 4 weeks, whereas at 8
weeks, neoplasia formation was detected in 50% of the eyes
in almost all layers of the eye, including the retina, vitreous,
and choroid [66]. These neoplasias expressed the character-
istics of the diﬀerent germ layers, so they were considered to
be teratomas. Even if ES cells seem fully diﬀerentiated into
dopamine neurons in vitro before transplantation, they still
carry the risk of tumorigenesis. For example, a rat PD model
grafted with mouse ES cells prediﬀerentiated into dopamine
neurons developed severe teratomas [67, 68]. Thus, ES cells
may provide treatment for degenerative disease in the future,
but their unlimited self-renewal and proliferative potential
pose the risk of tumor induction after engraftment, which is
ad i ﬃcult obstacle that must be overcome.
11.iPSCells
Induced pluripotent stem (iPS) cells, whose properties are
similar to those of ES cells, can be generated from adult
humancells,suchasdermalﬁbroblasts,byintroducinggenes
such as Sox2, Oct3/4, Klf-4, and c-Myc [69]. They have thus
attracted increasing attention as a new type of pluripotent
stem cell without major ethical concerns. As is the case
with ES cells, iPS cells can generate cells of all three germ
layers and have unlimited proliferative activity, but their
clinical application is limited by their tumorigenicity. iPS
cells can be induced to form dopamine neurons, but the
induction eﬃciency is generally lower than that of ES cells
and the quality of the cells is not homogenous [69, 70]. One
recent report suggested that iPS cells induced from mouse
ﬁbroblasts are able to integrate into the fetal brain, and can
improve symptoms in a rat PD model, but similar to ES cells,
they carry the risk of tumorigenesis [71].
12.Other Cells
Retinal pigment epithelium is a recent potential candidate
for cell therapy in PD because L-DOPA, which is produced
during the metabolic pathway of melanin in retinal pigment
epithelium, metabolizes to DOPA when taken up into the
glial and neuronal cells. The produced DOPA aﬀects PD
so that if retinal pigment epithelia survive and integrate
after transplantation, this strategy will be beneﬁcial [72].
The system will not be applicable for autocell transplan-
tation; however, so the cell sources remain a problem. In
phase I of study, retinal pigment epithelia collected from
cadaveric tissues were transplanted into PD patients, but no
antiparkinsonian beneﬁts have been recognized.
13.Perspectives
While ES cells and NSCs have great potential, MSCs provide
strong possibilities for clinical application, because they are
easily accessible cells with few ethical problems and can be
eﬃciently expanded in vitro to achieve therapeutic scale.
Importantly, MSCs are already widely used clinically to
treat osteoarthritis and myocardial infarction, so they have
an established record in clinical applications. Furthermore,
they are easily obtained from patients or marrow banks,
autologoustransplantation,ortransplantationwiththesame
HLA subtype from a healthy donor, which may minimize the
risks of rejection.
Although transplantation of naive MSCs is eﬀective
for treating PD, this is mostly due to the trophic eﬀects,
which do not persist for a long period. In addition, cell
transplantation via intravenous administration is known to
occasionally cause pulmonary thrombosis when the cells are
infused in a high concentration [73]. Therefore, from the
perspective of cell based therapy, it is desirable to transplant
functional dopamine neurons induced from MSCs directly
into the striatum of PD patients by stereotaxic operation
[17]. Because the dopamine neuron induction using NICD
transfection involves plasmid introduction, further long-
term studies are needed to ensure safety against tumor
formation and eﬃcacy of manipulated MSCs.
MSCs are usually harvested as adherent cells from
mesenchymal tissues and are thus a heterogeneous cell
population [10, 25]. Any of these types of adherent cells
could contaminate the MSC population, particularly in
the initial step of culture. In subsequent subcultures, the
cells seem to converge on general MSCs, and other cell
types are left out, but still MSCs do not comprise a single
homogeneous cell type. Therefore, the big picture of MSCs
is not yet clariﬁed, and in fact, a speciﬁc molecular marker
that is exclusively expressed by MSCs has yet to be found.
For these reasons, the entity of diﬀerentiation into dopamine
neurons remains an enigma. Indeed, MSCs show a trilineage
diﬀerentiation, but the diﬀerentiation ratio is usually not
very high and thus a subpopulation of MSCs seems to be
related to the diﬀerentiation. The pluripotent stem cells,
Muse cells, were identiﬁed in human mesenchymal tissues
and cells [25]. If the cells responsible for the diﬀerentiation
of dopamine neurons are clariﬁed, the potential of MSCs for
application to PD will be greatly advanced.
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